Filgotinib in Moderate-to-Severe Crohn’s Disease: A Network Meta-Analysis of Efficacy and Adverse Events

This network meta-analysis (NMA) evaluates the efficacy and safety of filgotinib at 100 mg and 200 mg doses compared to placebo in patients with moderate-to-severe CD. It combines direct and indirect evidence to assess clinical remission rates, patient-reported outcomes, endoscopic response, and adverse events, offering a detailed and dose-specific overview of filgotinib’s therapeutic profile.